Physical Activity to Reduce Cardiometabolic Risk in Adults With Serious Mental Illness (PARCS) Study
Launched by KANSAS STATE UNIVERSITY · Jul 10, 2022
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Adults with serious mental illness or serious mental illness (SMI) suffer from drastically higher rates of premature mortality (as much as a 10-25 years reduction in life expectancy) compared to the general population. Co-morbid medical conditions (i.e., heart disease, diabetes) are a fundamental cause. The iatrogenic cardiometabolic effects associated with antipsychotic drugs complicate matters. Underlying modifiable cardiometabolic risk factors (e.g., obesity, hypertension, poor physical fitness) are more prevalent and manifest earlier in the lifecourse in persons with SMI compared with t...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Authorized for peer group treatment through the behavioral health facility
- • Medically cleared to participate in physical activity (if indicated by ACSM 11th Edition pre-exercise participation screener)
- Exclusion Criteria:
- • Under 18 years of age
- • Unable to obtain physician clearance (if indicated by ACSM 11th Edition pre-exercise participation screener)
About Kansas State University
Kansas State University (KSU) is a leading research institution dedicated to advancing knowledge and improving health outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, KSU leverages its diverse expertise in veterinary and human medicine, agricultural sciences, and public health to conduct rigorous clinical research. The university is committed to ethical standards, participant safety, and the dissemination of impactful findings that contribute to the scientific community and society at large. Through its clinical trials, KSU aims to address pressing health challenges and foster the development of new therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Augusta, Georgia, United States
Junction City, Kansas, United States
Patients applied
Trial Officials
Gina M Besenyi, MPH, PhD
Principal Investigator
Kansas State University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials